Methods for treating hemolytic diseases and sickle cell disease

Abstract

The present disclosure generally relates to methods of treating hemolytic diseases such as sickle cell anemia using kinase inhibitors, for example, compounds that inhibit the spleen tyrosine kinase (SYK). In some embodiments a method is presented to prevent thrombosis in blood vessels of patients with a hemolytic disease comprising the step of: administrating to a patient having at least one hemolytic disease a therapeutically effective amount of at least one SYK inhibitor. In some embodiments the method includes repeatedly administering the SYK kinase inhibitor to a patient.

1 - 20 . (canceled) 
     
     
         21 . A method of treating sickle cell disease comprising administering to a subject in need of such treatment a therapeutically effective amount of a Syk kinase inhibitor. 
     
     
         22 . The method of  claim 21 , wherein the Syk kinase inhibitor is imatinib. 
     
     
         23 . The method of  claim 22 , wherein the imatinib is imatinib mesylate. 
     
     
         24 . The method of  claim 23 , which further comprises administering another Syk kinase inhibitor selected from the group consisting of a Syk kinase inhibitor II, a Syk kinase inhibitor IV, and a combination thereof. 
     
     
         25 . The method of  claim 23 , which further comprises administering a Syk kinase inhibitor selected from the group consisting of NVP-QAB205, a purine-2-benzamine derivative, a pyrimidine-5-carboxamide derivative, a 1,6-naphthyridine derivative, BAY 61-3606, piceatannol, 3,4-dimethyl-10-(3-aminopropyl)-9-acridone oxalate, R406, R788, R112, and combinations thereof. 
     
     
         26 . The method of  claim 23 , which further comprises administering one or more drugs to treat pain. 
     
     
         27 . A method of treating sickle cell disease comprising administering to a subject in need of such treatment a therapeutically effective amount of imatinib mesylate and another Syk kinase inhibitor selected from the group consisting of a Syk kinase inhibitor II, a Syk kinase inhibitor IV, and a combination thereof. 
     
     
         28 . The method of  claim 27 , which comprises administering a Syk kinase inhibitor selected from the group consisting of NVP-QAB205, a purine-2-benzamine derivative, a pyrimidine-5-carboxamide derivative, a 1,6-naphthyridine derivative, BAY 61-3606, piceatannol, 3,4-dimethyl-10-(3-aminopropyl)-9-acridone oxalate, R406, R788, R112, and combinations thereof.